Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Thermo Fisher (TMO) to $670 from $630 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s top line organic growth guide of 3%-4% came in slightly below expectations, but their operating margin expansion of 90bps was largely a surprise to investors given the more muted top line growth expectation for this year, the analyst tells investors in a research note. Thermo Fisher looks well positioned to deliver differentiated growth in 2025 through share gains due to their full service offering and instrument innovation, diversified end markets, and potential upside to guide as China stimulus orders flow through, the firm added.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Early notable gainers among liquid option names on January 30th
- Morning Movers: UPS and Cigna plunge double digits following Q4 results
- Thermo Fisher sees FY25 adjusted EPS $23.10-$23.50, consensus $23.18
- Thermo Fisher reports Q4 adjusted EPS $6.10, consensus $5.94
- Notable companies reporting before tomorrow’s open